Faecalibacterium is one of the most abundant and health-promoting bacteria in the human gut, typically making up around 5 to 7 percent of an adult’s total gut microbiome and detected in roughly 85 percent of gut samples worldwide. Its most studied species, now often called Faecalibacterium duncaniae (formerly F. prausnitzii), produces butyrate, a short-chain fatty acid that fuels the cells lining your colon and helps keep inflammation in check. Despite decades of research linking higher Faecalibacterium levels to better health outcomes, you still cannot walk into a pharmacy and buy it in a capsule, and the reasons for that gap are part of what makes this bacterium so fascinating.
What Faecalibacterium Does in Your Gut
The headline benefit of Faecalibacterium is butyrate production. Butyrate is the primary energy source for colonocytes, the cells that line the inside of your large intestine.1PubMed Central. mGem: Faecalibacterium, an important protector of gut health Without enough butyrate, those cells struggle to maintain the gut barrier, which is the thin but critical wall separating the contents of your intestine from the rest of your body. When that barrier weakens, bacterial fragments and inflammatory molecules can leak into the bloodstream, a process often called “leaky gut” in popular health writing.
Beyond fueling colonocytes, Faecalibacterium produces a unique protein researchers have named MAM, for Microbial Anti-inflammatory Molecule. MAM has been shown to interact with tight junction proteins, the molecular fasteners that hold gut lining cells together. In diabetic mice, supplementing with MAM restored intestinal barrier function and increased levels of the tight junction protein ZO-1.2PubMed Central. Faecalibacterium prausnitzii‐derived microbial anti‐inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression Researchers have identified at least ten distinct clusters of MAM proteins across different Faecalibacterium strains, suggesting this anti-inflammatory toolkit is more diverse than initially thought.3PubMed Central. Intraspecific Diversity of Microbial Anti-Inflammatory Molecule (MAM) from Faecalibacterium prausnitzii
Recent structural work has revealed that MAM assembles into a lattice-like hexameric structure on the bacterium’s outer surface, where it can interact directly with the host’s immune system.4PubMed Central. The Microbial Anti-Inflammatory Molecule (MAM) is a key protein processed and exported to Faecalibacterium duncaniae envelope That said, the picture is not perfectly clean. At least one lab study using a co-culture model found that live Faecalibacterium did not improve tight junction integrity in that particular experimental setup, which suggests the barrier benefits may depend heavily on context, such as whether inflammation is already present.5PubMed Central. Live Faecalibacterium prausnitzii Does Not Enhance Epithelial Barrier Integrity in an Apical Anaerobic Co-Culture Model of the Large Intestine
Inflammatory Bowel Disease and Crohn’s
The strongest clinical signal for Faecalibacterium comes from inflammatory bowel disease (IBD), especially Crohn’s disease. A landmark study analyzing the gut microbiota of Crohn’s patients found that reduced Faecalibacterium on the surface of surgically removed intestinal tissue was associated with a higher risk of the disease coming back within six months.6PubMed Central. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients A systematic review and meta-analysis of the broader literature confirmed this pattern: low Faecalibacterium counts were associated with shorter remission periods and more frequent relapses in IBD patients.7PubMed Central. Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature
This does not mean low Faecalibacterium causes Crohn’s. Chronic gut inflammation can itself drive down populations of oxygen-sensitive bacteria, creating a vicious cycle where disease begets more dysbiosis. But the consistency of the association across studies is why Faecalibacterium is now being tested directly in Crohn’s patients in clinical trials.
Metabolic Health and Type 2 Diabetes
The metabolic story parallels the IBD findings in an interesting way. In mouse models of type 2 diabetes, Faecalibacterium treatment lowered fasting blood glucose and improved insulin resistance without reducing body weight, suggesting the effect worked through the gut environment rather than through calorie changes.8PubMed Central. Faecalibacterium prausnitzii Improves Lipid Metabolism Disorder and Insulin Resistance in Type 2 Diabetic Mice A study in nonhuman primates reinforced this connection from the other direction: animals with higher fecal Faecalibacterium levels were protected from future type 2 diabetes diagnoses, while developing diabetes further depressed those levels.9PubMed Central. Faecalibacterium prausnitzii Indicates Healthspan and Lifespan in Nonhuman Primates
The same primate study found that higher Faecalibacterium abundance was linked to longer lifespan and better survival after physiological stress, with a modest but statistically significant effect size. These findings sit squarely in the “promising but preliminary” category. Animal studies of this kind show biological plausibility and help justify human trials, but they do not prove the same dynamics hold in people. A clinical trial specifically examining Faecalibacterium supplementation for glycemic control is already registered and underway.10Gut. Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium
Colorectal Cancer Connections
Colorectal cancer (CRC) is characterized by a specific microbiome shift: certain harmful bacteria tend to become more abundant while Faecalibacterium drops. In rat models, supplementing with Faecalibacterium significantly reduced the frequency of aberrant crypt foci, which are early precancerous changes in the colon lining, and also lowered markers of oxidative damage in colon tissue.11PubMed Central. Faecalibacterium prausnitzii Ameliorates Colorectal Tumorigenesis and Suppresses Proliferation of HCT116 Colorectal Cancer Cells In lab dishes, the compounds Faecalibacterium secretes directly suppressed the growth of a human colorectal cancer cell line in a dose-dependent manner.
One of the more intriguing mechanistic findings involves tryptophan, an amino acid found in many protein-rich foods. Faecalibacterium metabolizes tryptophan into picolinic acid, which appears to counteract the tumor-promoting effects of Bacteroides fragilis, a bacterium that tends to increase in CRC.12Gastroenterology. Revealing the Antagonistic Interactions of Faecalibacterium prausnitzii and Bacteroides fragilis in Colorectal Cancer This is a good example of how gut bacteria do not act in isolation. The balance between competing species matters as much as the absolute number of any one organism.
The Gut-Brain Connection
Research into the gut-brain axis has expanded rapidly in recent years, and Faecalibacterium has a role here too. In rats subjected to chronic stress to induce depression-like behavior, Faecalibacterium supplementation increased levels of short-chain fatty acids in the gut and the anti-inflammatory signaling molecule IL-10 in the bloodstream, while reducing the stress hormone corticosterone and inflammatory markers like IL-6. These changes correlated with reduced anxiety and depression-like behavior.13Psychoneuroendocrinology. Faecalibacterium prausnitzii (ATCC 27766) has preventive and therapeutic effects on chronic unpredictable mild stress-induced depression-like and anxiety-like behavior in rats
A more recent study tested a synbiotic combination of Faecalibacterium with prebiotic fibers (FOS and GOS) in a rat model of treatment-resistant depression. The combination normalized levels of key neurotransmitters including serotonin, GABA, noradrenaline, and dopamine in brain regions associated with mood regulation. It also boosted brain-derived neurotrophic factor, a protein critical for neuronal health, and shifted tryptophan metabolism away from the kynurenine pathway, which is associated with neuroinflammation.14European Journal of Pharmacology. Faecalibacterium prausnitzii, FOS and GOS loaded synbiotic reverses treatment-resistant depression in rats: Restoration of gut-brain crosstalk The emphasis on treatment-resistant depression is noteworthy, as that is precisely the population where new therapeutic approaches are most needed. But these remain animal models. The leap from rat brains to human psychiatric outcomes is notoriously unreliable, and no controlled human trials have yet confirmed these effects.
How to Increase Your Faecalibacterium Levels Through Diet
If you cannot buy Faecalibacterium in a pill, the practical question becomes: how do you encourage the population you already have to thrive? The answer centers on feeding it what it likes to eat, which is primarily fermentable fiber and related substrates.
Lab studies have tested a range of prebiotics for their ability to promote Faecalibacterium growth. Fructooligosaccharides (FOS), inulin, pectin, resistant starch, kiwifruit fiber, and even riboflavin (a B vitamin) all significantly accelerated growth rates compared to controls, with several showing clear dose-dependent effects. Pectin stood out as particularly effective at promoting both microbial function and immune-relevant responses.15PubMed Central. Improving Growth Dynamics of Faecalibacterium prausnitzii by Exposure to Prebiotics In practical dietary terms, pectin is abundant in apples, citrus fruits, and berries. Inulin and FOS are found in onions, garlic, leeks, asparagus, bananas, and chicory root. Resistant starch develops in cooked-and-cooled potatoes, rice, and legumes.
When Faecalibacterium grows on inulin specifically, it produces not only butyrate but also fructose, which in turn promotes the growth and viability of intestinal lining cells.16PubMed Central. Inulin-grown Faecalibacterium prausnitzii cross-feeds fructose to the human intestinal epithelium This is a nice illustration of how a single dietary input can trigger a cascade of beneficial effects.
At the broader dietary pattern level, the Mediterranean diet has been specifically associated with higher levels of Faecalibacterium and other butyrate-producing bacteria. The combination of plant-based foods, olive oil, polyphenols from fruits and vegetables, and moderate fiber intake creates a generally favorable environment for these organisms.17PubMed Central. Gut Microbiota Modulation Through Mediterranean Diet Foods: Implications for Human Health
Cross-Feeding and Why Bifidobacteria Matter
Faecalibacterium does not exist in isolation. It depends on other gut bacteria for some of its nutritional inputs, a process called cross-feeding. Bifidobacterium species break down complex carbohydrates and produce acetate as a byproduct. Faecalibacterium then takes up that acetate and converts it into butyrate. In co-culture experiments, growing Bifidobacterium adolescentis alongside Faecalibacterium led to higher butyrate production than Faecalibacterium could achieve alone, with acetate levels dropping as Faecalibacterium consumed it.18PubMed. Enhanced butyrate formation by cross-feeding between Faecalibacterium prausnitzii and Bifidobacterium adolescentis
This partnership even works in infants’ guts, where Bifidobacterium bifidum breaks down human milk oligosaccharides (complex sugars in breast milk) and releases the constituent sugars for Faecalibacterium to use, thereby boosting butyrate production early in life.19PubMed Central. HMOs Induce Butyrate Production of Faecalibacterium prausnitzii via Cross-Feeding by Bifidobacterium bifidum with Different Mechanisms for HMO Types The practical upshot is that supporting Bifidobacterium, whether through fermented foods like yogurt and kefir or through prebiotic fibers, indirectly supports Faecalibacterium as well. You are feeding an ecosystem, not a single species.
Exercise and Lifestyle Factors
Regular physical activity has been linked to increased abundance of butyrate-producing bacteria including Faecalibacterium and Roseburia, with downstream improvements in glucose metabolism and insulin sensitivity.20Cell Reports. Exercise-driven gut microbiota alterations enhance colonization resistance against methicillin-resistant Staphylococcus aureus The mechanism likely involves exercise-induced changes to intestinal transit time, blood flow to the gut, and shifts in the availability of oxygen and nutrients along the colon wall, but the exact pathways are still being worked out.
Population-level data adds another wrinkle. Faecalibacterium abundance tends to be higher in non-Westernized populations, suggesting that modern diets low in fiber and high in processed food, along with other lifestyle factors like antibiotic use, have disrupted what was once a more reliable human-microbe partnership.21Oxford Academic (FEMS Microbiology Reviews). Faecalibacterium: a bacterial genus with promising human health applications Levels also vary by age and possibly by sex, with lower abundance in newborns, children, and the elderly, and potentially lower levels in women than in men. This age-related pattern makes sense biologically: Faecalibacterium takes time to establish in infant guts and may decline as the immune system and diet shift in old age.
Why You Cannot Just Buy It as a Supplement
Faecalibacterium is an extremely strict anaerobe, meaning it dies when exposed to oxygen. In one experiment, exposing Faecalibacterium colonies to room air for just 20 minutes killed all of them.22PubMed Central. Synergy and oxygen adaptation for development of next-generation probiotics This makes every step of the supplement manufacturing process, from growing it to freeze-drying it, shipping it, and getting it into the consumer’s gut alive, extraordinarily difficult. Traditional probiotic bacteria like Lactobacillus and Bifidobacterium can tolerate at least brief oxygen exposure, which is why they dominate the supplement aisle. Faecalibacterium cannot.
Researchers have identified this as one of the central bottlenecks in translating microbiome science into therapy. Beyond oxygen sensitivity, there is the challenge that butyrate producers like Faecalibacterium function within complex cross-feeding networks, meaning a single-strain approach may not work as well as an ecological one that includes partner species.23PubMed Central. Butyrate-Producing Bacteria in Intestinal Disease Therapy: Potential and Challenges And the host’s own physiology matters too. Butyrate can be protective in some contexts and permissive of disease in others, making blanket supplementation less straightforward than it sounds.
Two main technological approaches are being pursued. One is microencapsulation, where bacteria are sealed inside protective coatings that shield them from oxygen and stomach acid during transit, then release them in the colon. Advanced versions of these capsules can respond to pH changes or even inflammation signals to release their contents in the right place.24PubMed Central. Next-Generation Microencapsulation Technologies for Probiotic Protection and Precision Delivery The other approach involves gradually training Faecalibacterium to tolerate oxygen. By exposing bacterial populations to slowly increasing oxygen levels over time, researchers have developed an oxygen-tolerant strain that still produces butyrate and has been well tolerated in both mice and humans at doses up to five billion colony-forming units.10Gut. Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium
Clinical Trials Already Underway
Faecalibacterium has moved beyond the lab-curiosity stage. As of recent registrations, clinical trials are testing it in Crohn’s disease, advanced non-small cell lung cancer that has stopped responding to immunotherapy, and glycemic control. These trials use the regulatory framework for “live biotherapeutic products,” a classification distinct from conventional probiotics or drugs, which has its own manufacturing and safety requirements. The fact that an oxygen-tolerant strain exists and has passed early safety testing in humans is a meaningful milestone. Whether it will produce clinically significant benefits in controlled human trials remains an open question.
Medications That Shift Faecalibacterium Levels
Your medications may be quietly reshaping your Faecalibacterium population in either direction. SGLT2 inhibitors, a class of diabetes drugs that work by preventing glucose reabsorption in the kidneys, have been shown in clinical studies to increase levels of butyrate-producing bacteria including Faecalibacterium.25PubMed Central. Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome This raises the intriguing possibility that some of the metabolic benefits of these drugs are partially mediated through the gut microbiome rather than solely through kidney glucose handling.
On the other side, broad-spectrum antibiotics are well known to reduce Faecalibacterium populations, sometimes dramatically. Because the bacterium is so oxygen-sensitive and slow to re-establish, antibiotic-driven losses can take weeks or months to recover from, especially if your diet does not supply the prebiotic fibers needed to support regrowth. Proton pump inhibitors (PPIs) used for acid reflux have also been associated with altered gut microbiome composition, though the specific impact on Faecalibacterium varies across studies. If you are on long-term medication and concerned about your gut microbiome, this is a conversation worth having with your doctor, though the honest answer is that personalized microbiome management based on medication profiles is still in its infancy.
When Faecalibacterium Levels Are Naturally Low
A metagenomic analysis of over 7,900 human samples found that while the mean relative abundance of Faecalibacterium in adults is around 6.5 percent and the median about 4.8 percent, individual values range enormously, from nearly undetectable to as high as 75 percent of total gut bacteria.21Oxford Academic (FEMS Microbiology Reviews). Faecalibacterium: a bacterial genus with promising human health applications That 15-fold range between median and maximum tells you that “normal” is a very broad target.
Certain life stages naturally feature low Faecalibacterium. Newborns have very little of it, and it builds gradually through childhood as the gut microbiome matures. Elderly adults also tend to have lower levels, which may relate to reduced dietary fiber intake, changes in intestinal physiology, and increased medication use. If you are older and eating a low-fiber diet while taking multiple medications, your Faecalibacterium population faces headwinds from several directions simultaneously.
Geography matters too. People living traditional, non-industrialized lifestyles tend to carry more Faecalibacterium than those in Westernized societies, a finding that aligns with the general observation that modern diets and lifestyles have reduced gut microbial diversity overall. This is not a nostalgic argument for pre-industrial living. It is a data point suggesting that some of the dietary inputs Faecalibacterium evolved to depend on, particularly diverse plant fibers, have largely disappeared from the average Western plate. Deliberately reintroducing variety in your fiber sources, rather than relying on a single supplement like psyllium husk, is probably the most practical step most people can take.